AC Immune Unveils Novel Neurodegenerative Drug Candidates
Ticker: ACIU · Form: 6-K · Filed: Jul 31, 2024 · CIK: 1651625
| Field | Detail |
|---|---|
| Company | Ac Immune SA (ACIU) |
| Form Type | 6-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: drug-development, biotech, pipeline-update, neurodegenerative-disease
TL;DR
AC Immune just dropped a new class of Alzheimer's drug candidates (morADC) at AAIC 2024 - big news for neurodegenerative disease treatment!
AI Summary
On July 31, 2024, AC Immune SA announced the unveiling of morADC, a new class of drug candidates for neurodegenerative diseases. This announcement was made via a press release and an oral presentation at the Alzheimer's Association International Conference (AAIC 2024) in Philadelphia, PA, which runs from July 28 to August 1, 2024. MorADC technology merges brain-penetrant Morphomers® with SupraAntigen® monoclonal antibodies.
Why It Matters
This development could lead to new therapeutic options for patients suffering from neurodegenerative diseases like Alzheimer's, potentially offering a novel approach to treatment.
Risk Assessment
Risk Level: medium — The development of new drug candidates is inherently risky, with high failure rates in clinical trials and regulatory approval processes.
Key Players & Entities
- AC Immune SA (company) — Registrant
- morADC (drug_candidate_class) — Novel drug candidates for neurodegenerative diseases
- Morphomers® (technology) — Component of morADC
- SupraAntigen® (technology) — Component of morADC
- Alzheimer's Association International Conference (AAIC 2024) (event) — Venue for announcement
- July 31, 2024 (date) — Date of announcement
FAQ
What is the specific mechanism of action for morADC drug candidates?
The filing states that morADC combines proprietary brain-penetrant small molecule Morphomers® with SupraAntigen® monoclonal antibodies, but does not detail the specific mechanism of action.
What neurodegenerative diseases are targeted by morADC?
The filing broadly mentions 'neurodegenerative disease-fighting drug-candidates' and the announcement was made at the Alzheimer's Association International Conference, implying Alzheimer's is a key target, but specific diseases are not enumerated.
When will clinical trials for morADC candidates begin?
The filing does not provide information on the timeline for the commencement of clinical trials for morADC candidates.
Are there any specific dollar amounts associated with the development or potential of morADC mentioned in this filing?
No specific dollar amounts related to the development or potential of morADC are mentioned in this 6-K filing.
What is the regulatory status of morADC candidates?
The filing describes morADC as a 'novel class of neurodegenerative disease-fighting drug-candidates' and does not mention any specific regulatory status or approvals.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2024-07-31 08:35:09
Filing Documents
- dp215741_6k.htm (6-K) — 11KB
- dp215741_ex9901.htm (EX-99.1) — 19KB
- image_001.jpg (GRAPHIC) — 52KB
- 0000950103-24-011251.txt ( ) — 103KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission file number: 001-37891 AC IMMUNE SA (Exact Name of Registrant as Specified in Its Charter) EPFL Innovation Park Building B 1015 Lausanne, Switzerland (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On July 31, 2024, AC Immune SA issued a press release announcing that it had unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC (Morphomer ® Antibody Drug Conjugate) in an oral presentation at the annual Alzheimer’s Association International Conference (AAIC 2024), taking place from July 28 – August 1, 2024, in Philadelphia, PA. MorADC combines proprietary brain-penetrant small molecule Morphomers ® with SupraAntigen ® monoclonal antibodies, forming a new class of drug-candidates to target toxic proteins in the central nervous system. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 6-K. This Report on Form 6-K (other than Exhibit 99.1 hereto) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. 333-227016, 333-249655, 333-255576 and 333-277940) and Form S-8 (File Nos. 333-213865, 333-216539 and 333-233019) of AC Immune SA and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated July 31, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AC IMMUNE SA By: /s/ Andrea Pfeifer Name: Andrea Pfeifer Title: Chief Executive Officer By: /s/ Christopher Roberts Name: Christopher Roberts Title: Chief Financial Officer Date: July 31, 2024